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Abstract 
Intracellular Ca2+ signals that arise from the endoplasmic reticulum (ER), the major intracellular Ca2+-
storage organelle, impact several mitochondrial functions and dictate cell survival and cell death 
processes. Furthermore, alterations in Ca2+ signaling in cancer cells promote survival and establish a 
high tolerance towards cell stress and damage, so that the on-going oncogenic stress does not result 
in the activation of cell death. Over the last years, the mechanisms underlying these oncogenic 
alterations in Ca2+ signaling have started to emerge. An important aspect of this is the identification 
of several major oncogenes, including Bcl-2, Bcl-XL, Mcl-1, PKB/Akt, and Ras, and tumor suppressors, 
such as p53, PTEN, PML, BRCA1, and Beclin 1, as direct and critical regulators of Ca2+-transport 
systems located at the ER membranes, including IP3 receptors and SERCA Ca
2+ pumps. In this way, 
these proteins execute part of their function by controlling the ER-mitochondrial Ca2+ fluxes, favoring 
either survival (oncogenes) or cell death (tumor suppressors). Oncogenic mutations, gene deletions 
or amplifications alter the expression and/or function of these proteins, thereby changing the 
delicate balance between oncogenes and tumor suppressors, impacting oncogenesis and favoring 
malignant cell function and behavior. In this review, we provided an integrated overview of the 
impact of the major oncogenes and tumor suppressors, often altered in cancer cells, on Ca2+ signaling 
from the ER Ca2+ stores. 
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List of abbreviations 
a.a.: amino acid 
ATP: adenosine triphosphate 
BH domain: Bcl-2-homology domain 
BI-1: Bax inhibitor-1 
BIRD-2: Bcl-2/IP3R disruptor-2 
BRCA1: breast and ovarian cancer susceptibility gene 1 
[Ca2+]cyt: cytosolic Ca
2+ concentration 
CLL: chronic lymphocytic leukemia 
DL-BCL: diffuse large B-cell lymphoma 
ER: endoplasmic reticulum 
GAP: GTPase-activating protein 
IICR: IP3-induced Ca
2+ release 
IP3R: inositol 1,4,5-trisphosphate receptor 
MAM: mitochondria-associated ER membrane 
MCU: mitochondrial calcium uniporter 
MEF: mouse embryonic fibroblast 
MOMP: mitochondrial outer membrane permeabilization  
mPTP: mitochondrial permeability transition pore 
mTOR: mammalian target of rapamycin 
OMM: outer mitochondrial membrane 
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PDK1: phosphatidylinositol-dependent kinase 1 
PDT: photodynamic therapy 
PEST region: proline/glutamic acid/serine/threonine-containing region 
PI3K: phosphoinositide 3-kinase 
PIP2: phosphatidylinositol 4,5-bisphosphate 
PIP3: phosphatidylinositol 3,4,5-trisphosphate 
PKB: protein kinase B 
PKC: protein kinase C 
PLC: phospholipase C 
PML: promyelocytic leukemia protein 
PP2A: protein phosphatase 2A 
PTEN: phosphatase and tensin homolog deleted on chromosome 10 
RA2: Ras-associating domain 2 
ROS: reactive oxygen species 
RyR: Ryanodine receptor 
SERCA: sarco/endoplasmic reticulum Ca2+-ATPase 
tBid: truncated Bid 
TCR: T-cell receptor 
TKO DT40 cells: triple-IP3R-knockout DT40 cells 
VDAC1: voltage-dependent anion channel 1 
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Introduction 
Intracellular Ca2+ signals regulate cell function and cell survival by controlling many processes. Ca2+ 
pumps, Ca2+ channels, Ca2+ exchangers and Ca2+-binding proteins present at the plasma membrane 
and in different cellular compartments tightly control the cytosolic Ca2+ concentration ([Ca2+]cyt) [1–
3]. In resting condition, the [Ca2+]cyt is maintained at a concentration of approximately 100 nM, 
whereas the extracellular [Ca2+] is about 1 mM [1,4]. In response to various stimuli, the intracellular 
[Ca2+] can increase to the micromolar range in the cytosol [1–3] and reach 10 M and higher in 
microdomains like the interface between the endoplasmic reticulum (ER) and the mitochondria [5,6]. 
This [Ca2+] increase can be evoked by mobilizing Ca2+ from intracellular stores, such as ER and Golgi 
apparatus, or by Ca2+ entry from the extracellular environment [1–4]. The free [Ca2+] in the ER, the 
main intracellular Ca2+ store, varies around 500 µM [7]. Although the free [Ca2+] is around 500 µM, 
the total [Ca2+] in the ER is more than 2 mM as a result of the action of different Ca2+ buffering 
proteins such as calreticulin, Grp94 and BiP. These proteins bind Ca2+ with low affinity and high 
capacity [7]. The sarco/endoplasmic reticulum Ca2+-ATPase (SERCA), localized in the ER membrane, 
lowers the [Ca2+]cyt by pumping Ca
2+ from the cytosol into the ER in an adenosine triphosphate (ATP)-
dependent manner [8]. On the other hand, inositol 1,4,5-trisphosphate receptors (IP3Rs) release Ca
2+ 
from the ER store, allowing it to function as an intracellular messenger in several signal transduction 
pathways [9]. The IP3R, of which three isoforms exist (IP3R1, IP3R2, and IP3R3), is activated by 
elevated cytosolic levels of IP3, produced by phospholipase C (PLC) after stimulation of G-protein-
coupled receptors or receptor tyrosine kinases by hormones, growth factors or antibodies [9–11]. 
IP3R activity is regulated by Ca
2+ itself as well. Depending on the intracellular [Ca2+], Ca2+ either 
activates (low [Ca2+]cyt) or inhibits (high [Ca
2+]cyt) the channel [12–14]. Furthermore, regulatory 
proteins [9,10,15], protein kinases and phosphatases [16] and ATP [17–20] also modulate the Ca2+-
flux properties of the IP3R. Ca
2+ released from the ER can be efficiently accumulated by the 
mitochondria, thereby directly impacting several mitochondrial functions [21–23]. Ca2+ is transferred 
across the outer mitochondrial membrane (OMM) by voltage-dependent anion channel 1 (VDAC1), a 
weakly anion-selective channel that is permeable to Ca2+ as well [24,25]. Subsequently, the 
mitochondrial calcium uniporter (MCU) complex removes Ca2+ from the mitochondrial 
intermembrane space and imports Ca2+ into the matrix, a process that is driven by the negative 
mitochondrial membrane potential generated by electron transport [26]. In the mitochondria-
associated ER membranes (MAMs), which are mitochondria-associated ER subfractions involved in 
multiple cellular processes, including lipid synthesis, ER stress, autophagy and apoptosis, ER-
mitochondrial Ca2+ transport is facilitated by coupling of the IP3R to VDAC1 via glucose regulated 
protein 75 [27,28]. 
Intracellular Ca2+ signaling impacts many cellular processes, including mitochondrial bioenergetics, 
senescence, mitophagy, autophagy, and apoptosis [29–33]. First, mitochondrial bioenergetics are 
maintained by constitutive low-level IP3R-mediated Ca
2+ transfer from the ER to the mitochondria 
[29]. Ca2+ stimulates mitochondrial respiration and ATP production by promoting the activities of the 
Ca2+-dependent rate-limiting enzymes of the tricarboxylic acid cycle, i.e. alpha-ketoglutarate, 
isocitrate and pyruvate dehydrogenases [34]. Importantly, absence of constitutive low-level ER-
mitochondrial Ca2+ signaling results in inhibition of the aforementioned dehydrogenases and can lead 
to activation of AMP-activated protein kinase, stimulating pro-survival mammalian target of 
rapamycin (mTOR)-independent autophagy [29,32]. Second, apoptosis is another process depending 
on intracellular Ca2+ signaling. In cells suffering from varying forms of stress or damage, excessive 
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Ca2+ is released from the ER through the IP3R and transferred to the mitochondria via VDAC1 and 
MCU, causing mitochondrial Ca2+ overload [35]. This in turn leads to opening of the mitochondrial 
permeability transition pore (mPTP) [36], loss of mitochondrial membrane potential, 
permeabilization and rupture of the OMM and subsequent release of mitochondrial pro-apoptotic 
factors from the intermembrane space into the cytosol, such as cytochrome c, apoptosis-inducing 
factor and endonuclease G. Recently, the disassembly of respiratory chain complex II due to loss of 
cardiolipin was proposed to be responsible for cell death triggered in response to mitochondrial Ca2+ 
overload [37]. Third, intracellular Ca2+ is also an important regulator of macro-autophagy, a lysosomal 
degradation process disposing long-lived proteins, protein aggregates, damaged organelles and 
intracellular pathogens [32,38–41]. In this way, macro-autophagy, which will be further referred to as 
autophagy, maintains cellular homeostasis and promotes cell survival during stress conditions, 
though cell death is induced if the stress is too high or persists for a longer time [38,42]. Depending 
on the cellular state, intracellular Ca2+ signaling either inhibits or stimulates autophagy [42]. In 
healthy cells, basal autophagy is suppressed by small, spontaneous IP3R-mediated Ca
2+ signals 
transferred from the ER into the mitochondria that drive ATP production [29,32]. In contrast, Ca2+ 
signaling is enhanced in stressed cells, leading to elevated [Ca2+]cyt that promotes autophagy by 
activating autophagy-stimulating proteins, such as Ca2+/Calmodulin-dependent protein kinase kinase-
β [42,43]. Besides the control of macro-autophagy by intracellular Ca2+ signaling, also mitophagy, a 
process by which excessive or damaged mitochondria are removed, is modulated by Ca2+ uptake into 
the mitochondria: mitochondrial structure, membrane potential and reactive oxygen species (ROS) 
are not only important regulators of the Ca2+ uptake capacity of the mitochondria, but also 
determine whether or not to trigger mitophagy [31]. Finally, intracellular Ca2+ signaling plays an 
important role in cellular senescence, a protective mechanism against oncogenic events and 
tumorigenesis [30]. Loss of retinoblastoma and p53 pathways are usually involved in senescence, but 
recently it was revealed that the IP3R2 and MCU regulate this process as well [30]. Cells escaped 
oncogene-induced and replicative senescence by loss of IP3R2 as well as loss of MCU, since IP3R2-
mediated Ca2+ release and subsequent mitochondrial Ca2+ accumulation through MCU lead to a 
decreased mitochondrial membrane potential, followed by ROS production and accumulation and 
eventually senescence.  
During the last years, it has become clear that the remodeling of intracellular Ca2+ signaling pathways 
is a hall-mark of cancer cells that favors their survival and augments their cell death resistance [44–
47]. Many tumor cells display altered expression levels of proteins, including oncogenes and tumor 
suppressors that have functions at the MAMs and directly impact ER-mitochondrial Ca2+ transfer (Fig. 
1) [48]. Oncogenes promote cell survival by suppressing pro-apoptotic ER-mitochondrial Ca2+ 
signaling events, whereas tumor suppressors stimulate these ER-mitochondrial Ca2+ fluxes. Hence, it 
is not surprising that toxic Ca2+ signaling events are circumvented in cancer cells by the upregulation 
of oncogenes and/or the downregulation of tumor suppressors. The Ca2+-mediated cell death 
response is modulated either directly or indirectly in cancer cells. Cell death is escaped indirectly in 
tumor cells by a lowered ER Ca2+ content which prevents toxic, pro-apoptotic Ca2+ signals emanating 
from the ER and avoids mitochondrial Ca2+ overload (Fig. 2) [46,47]. For example, the oncogenes Mcl-
1, Bcl-2 and Bcl-XL lower the ER store content by stimulating IP3Rs outside of the MAMs, thereby 
increasing Ca2+ leak from the ER. Oncogenes Bcl-2 and Ras also decrease the ER Ca2+ levels by 
inhibiting the SERCA pump or by lowering SERCA2b expression levels, respectively. On the other 
hand, p53, which is frequently mutated in tumor cells, increases the ER store content by stimulating 
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SERCA activity. Apoptotic cell death can also be circumvented in cancer cells by a direct modulation 
of toxic ER-mitochondrial Ca2+ signaling events (Fig. 3) [46,48–50]. This occurs through an 
upregulation of oncogenes that inhibit excessive, toxic Ca2+ signals, including Bcl-2 and PKB/Akt, 
which both inhibit the IP3R, and Bcl-XL, which inhibits VDAC1. In contrast, tumor suppressors that 
promote pro-apoptotic Ca2+ signaling events are downregulated or mutated in cancer cells. This 
includes PTEN and BRCA1, which stimulate IP3Rs in the MAMs. The direct and indirect modulation of 
pro-apoptotic Ca2+ transfers from the ER to the mitochondria by oncogenes and tumor suppressors 
will be discussed in detail in the paragraphs below. Furthermore, oncogenes that sensitize IP3Rs to 
low levels of IP3, such as Bcl-XL and Mcl-1, enhance pro-survival Ca
2+ oscillations and stimulate 
mitochondrial bioenergetics by enhancing ATP production, hence preserving cell proliferation and 
cell survival (Fig. 4) [46]. The present review aims to offer a thorough discussion of the various 
oncogenes and tumor suppressors that are most often altered in cancer cells and influence Ca2+ 
signaling from the ER.  
 
Bcl-2 
Bcl-2 is a proto-oncogene localized at the mitochondria and the ER that serves as an anti-apoptotic 
protein by preventing mitochondrial outer membrane permeabilization (MOMP) [51–53]. Bcl-2 is the 
founding member of the Bcl-2-protein family, which consists of different anti-apoptotic and pro-
apoptotic members [54,55]. At the mitochondria, Bcl-2 scaffolds and neutralizes pro-apoptotic 
proteins like Bax/Bak and activator BH3-only proteins such as Bim and truncated Bid (tBid), thereby 
hindering the activation and oligomerization of Bax/Bak [51,52]. Bcl-2’s anti-apoptotic function is 
counteracted by sensitizer BH3-only proteins, like Bad, Puma and Noxa. At the ER, Bcl-2 prevents 
excessive Ca2+ signaling that would lead to mitochondrial Ca2+ overload and opening of the mPTP 
[56]. At the structural level, the anti-apoptotic Bcl-2 protein is organized in different Bcl-2-homology 
(BH) domains, including the BH4, BH3, BH1 and BH2 domain, and a C-terminal transmembrane 
domain for anchoring in membranes of intracellular organelles, including the mitochondria and the 
ER [57]. The BH3-BH1-BH2 domains together form a hydrophobic cleft, which targets and scaffolds 
the BH3 domain of pro-apoptotic Bcl-2-family members, such as the multidomain proteins Bax/Bak 
and the BH3-only proteins Bim, Bid and Bad. Bcl-2 expression is dysregulated in a variety of cancers, 
including chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DL-BCL) and non-small 
cell lung cell carcinoma [58–60]. In these cancers, the Bcl-2-expression levels are upregulated. 
Different mechanisms for Bcl-2 upregulation in cancers have been identified, including (i) a 
chromosomal translocation t(14;18) [58,61], which places Bcl-2 under the control of an IgG promoter 
sequence, (ii) downregulation of endogenous miRNA targeting Bcl-2 [62], and (iii) hypomethylation of 
the Bcl-2 gene resulting in an altered epigenetic regulation of Bcl-2 [63]. 
The impact of anti-apoptotic Bcl-2 on the ER Ca2+ homeostasis and dynamics is complex. Different but 
not mutually exclusive models have been proposed for ER-localized Bcl-2. Earlier work showed that 
anti-apoptotic Bcl-2 lowered the steady-state ER Ca2+-store content (Fig. 2) [64–66], thereby 
protecting the mitochondria from Ca2+ overload. Several underlying mechanisms were proposed, 
including Bcl-2 as a Ca2+-leak channel [67], Bcl-2 as an IP3R sensitizer [68,69] and Bcl-2 as a SERCA 
regulator [70]. (i) The original proposal that Bcl-2 could function as a putative Ca2+-pore-forming 
protein [67] has been excluded by a study showing that the effects of Bcl-2 in Ca2+ signaling were not 
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dependent on its putative pore-forming domain [71]. (ii) Bcl-2’s function as an IP3R sensitizer was 
supported by evidence from Bax/Bak-knockout mouse embryonic fibroblasts (MEF cells), which 
display an increased ratio of Bcl-2 over Bax/Bak [68]. Bax/Bak-knockout MEF cells displayed a 
decreased ER Ca2+-store content that was due to an increased sensitivity of IP3Rs towards its agonist 
IP3. As such, in the presence of excess Bcl-2, hypersensitive IP3Rs could become activated at basal IP3 
levels, thereby promoting the basal Ca2+ leak from the ER through open IP3R channels and lowering 
the steady state ER Ca2+ levels. At the molecular level, IP3R sensitization was due to an increased 
protein kinase A-dependent phosphorylation on Ser1755 [68]. Follow-up work implicated an even 
more complex regulation of the Bcl-2-dependent IP3R phosphorylation status, involving a role for 
calcineurin and protein phosphatase 1/Inhibitor-1 [72–74]. Also, the effect of Bcl-2 on ER Ca2+-store 
content appears to be dynamically regulated by phosphorylation. Bcl-2 phosphorylation mediated by 
c-Jun N-terminal protein kinase, neutralizing its anti-apoptotic properties, counteracts Bcl-2’s ability 
to lower ER Ca2+ levels [75]. Another mechanism for the IP3R sensitization by Bcl-2 has also been 
proposed. Bcl-2 was found to directly bind the C-terminal part of the IP3R channel, i.e. a domain that 
is in close proximity to the Ca2+-channel pore domain (Fig. 5) [69]. Bcl-2 targeted the 6th 
transmembrane domain of the IP3R, thereby sensitizing the channel and promoting pro-survival Ca
2+ 
oscillations linked to enhanced mitochondrial bioenergetics (Fig. 4). Hence, the C-terminal site in IP3R 
responsible for Bcl-2 binding corresponded to the site previously identified for Bcl-XL [76,77]. The 
affinity of the binding of Bcl-2 to the C-terminal IP3R domain has not been determined. Bcl-2 
overexpression in DT40 cells caused a lowering of the ER Ca2+ levels in an IP3R-dependent manner 
[69]. Consistent with this, Bcl-2 overexpression was more effective in protecting IP3R-expressing than 
IP3R-deficient DT40 cells against pro-apoptotic stimuli. (iii) Bcl-2 has been shown to directly interact 
with various SERCA isoforms (SERCA1 and SERCA2b), thereby limiting their ER Ca2+-uptake activity 
(Fig. 2) [70,78]. The binding of Bcl-2 to SERCA has also been proposed to destabilize the SERCA 
protein, thereby lowering its protein levels. 
Besides its effect on the ER Ca2+-store content, Bcl-2 can also directly control ER Ca2+-release 
mechanisms without impacting the ER Ca2+-store content [79–81]. Bcl-2 directly interacts with the 
three isoforms of the IP3R channel, thereby inhibiting their function (Fig. 3). Bcl-2 overexpression in 
immature T cells expressing low Bcl-2 levels suppressed IP3R-mediated Ca
2+ release elicited by strong 
T-cell receptor (TCR) stimulation or by a cell-permeable version of IP3 [80,82]. Remarkably, Bcl-2 did 
not suppress Ca2+ signals triggered by weak TCR stimulation. This suggests that Bcl-2 mainly 
suppresses excessive, pro-apoptotic Ca2+ signaling events but not pro-survival Ca2+ signaling events 
like Ca2+ oscillations. The frequency of these Ca2+ oscillations even appeared to be stimulated, 
supporting a putative sensitizing effect of Bcl-2 on IP3Rs under certain circumstances. In addition, Bcl-
2 directly regulated the channel properties of the IP3R, since purified Bcl-2 could suppress IP3R single-
channel activity and could interact with purified IP3R domains [80]. The Bcl-2 domain responsible for 
IP3R interaction and inhibition was the N-terminal BH4 domain [83]. This domain was essential and 
sufficient for binding IP3Rs, suppressing IP3R-mediated Ca
2+-flux properties and protecting against 
apoptotic stimuli. The binding of the central IP3R domain to BH4-Bcl-2 occurred with an apparent 
affinity in the low M range, while the IC50 for the inhibition of IP3-induced Ca
2+ release by BH4-Bcl-2 
in permeabilized cell systems was about 30 M [83,84]. The alpha-helical properties of the BH4 
domain and the presence of Lys17 in the center of this domain were critical for IP3R interaction and 
regulation [84,85]. Bcl-2 binding to IP3R was mapped to a region of 20 amino acids (a.a. 1389-1408 in 
the mouse IP3R1), located in the central, modulatory domain of the channel (Fig. 5) [86]. A peptide 
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corresponding to this Bcl-2-binding site on IP3Rs was sufficient to disrupt IP3R/Bcl-2-complex 
formation [86], thereby augmenting TCR-triggered IP3R-mediated Ca
2+ release and apoptosis without 
being cytotoxic by itself [86]. A modified version of this peptide coupled to TAT and stabilized (called 
BIRD-2 for Bcl-2/IP3 receptor disruptor-2) triggered spontaneous, large Ca
2+-signaling events that 
resulted in apoptotic cell death in CLL cells [87]. Similar results were obtained in DL-BCL cells, in 
which the sensitivity of the cancer cells correlated with the expression level of the IP3R2, the IP3R 
isoform with the highest sensitivity towards its ligand IP3 [88]. Furthermore, DL-BCL cells that were 
less sensitive to BH3 mimetics were more sensitive to BIRD-2 and vice versa, suggesting a dual role 
for Bcl-2 in B-cell cancers at both the mitochondria and the ER [49]. Not only CLL and DL-BCL cells but 
also multiple myeloma, follicular lymphoma and small cell lung cancer cells appeared to be 
dependent on the BH4-domain biology of Bcl-2 and thus were sensitive to BIRD-2 treatment [89,90]. 
Moreover, in vivo injection of BIRD-2 suppressed the in vivo growth of multiple myeloma cancer cells 
xenografted on immunodeficient mice [89]. Prolonged exposure of multiple myeloma cancer cells to 
BIRD-2 resulted in an increase in Bim levels, thereby sensitizing cancer cells towards the BH3-mimetic 
drugs ABT-263 and ABT-199 [89]. This was further supported by evidence in small cell lung cancer 
cells, in which ABT-263 potentiated BIRD-2-induced cell death [90]. Moreover, BIRD-2-induced cell 
death could be potentiated by other Bcl-2 inhibitors that also impact Ca2+-transport systems like 
HA14-1 [91]. BIRD-2 can trigger Ca2+-induced apoptosis through both caspase-dependent and 
caspase-independent mechanisms, since caspase inhibitors suppressed BIRD-2-induced cell death in 
Bcl-2-positive lymphoid malignancies [89] but not in small cell lung cancer cells [90]. In the latter, 
BIRD-2-induced apoptosis was counteracted by calpain inhibitors. 
The “dual” role of Bcl-2 as a dampener of the ER Ca2+-store content or as a direct inhibitor of the IP3R 
not affecting the ER Ca2+-store content has been causing controversy in the field [92]. Yet, the varying 
effect of Bcl-2 on ER Ca2+ could be explained by different factors. First, the reduced ER Ca2+ levels 
upon Bcl-2 overexpression might be mediated by a downstream ER Ca2+-leak pathway that is 
activated by Bcl-2. For instance, Bcl-2 interacts with Bax Inhibitor-1 (BI-1), an ER-located Ca2+-leak 
channel belonging to the transmembrane Bax Inhibitor-1 motif-containing protein family [93–96]. 
Interestingly, Bcl-2 overexpression only lowered the steady state ER Ca2+ levels in BI-1-expressing 
cells but not in BI-1-knockout cells [97], indicating that Bcl-2 may lower the ER Ca2+-store content in a 
BI-1-dependent manner. Second, the effect of Bcl-2 on ER Ca2+ might be cell type dependent. For 
instance, high expression levels of IP3R3 in certain cell types might favor Bcl-2’s ability to lower ER 
Ca2+ levels as shown in the DT40 triple-IP3R knockout cell system in which Bcl-2 only lowered the ER 
Ca2+ content in IP3R3-expressing cells. Third, the cellular effects of Bcl-2 have also been shown to 
depend on its localization and its concentration. For instance, transient overexpression of 
mitochondrially-targeted Bcl-2 or wild-type Bcl-2, but not ER-targeted Bcl-2, could actually induce 
apoptosis in certain cells [98]. Furthermore, this effect might be dependent on its cellular 
concentration, since excessive overexpression has been implicated to trigger apoptosis [99]. Hence, 
the lowering of the ER Ca2+-store content in stably Bcl-2-overexpressing cells might be a 
compensatory mechanism. 
Besides IP3Rs, Bcl-2 proteins also target and inhibit ryanodine receptors (RyRs) [100], another class of 
intracellular Ca2+-release channels. All RyR isoforms (RyR1, RyR2 and RyR3) interacted with Bcl-2. The 
binding of Bcl-2 to RyRs occurred via its central domain, consistent with the fact that the stretch of 
amino acids responsible for Bcl-2 binding to the IP3R binding is highly conserved in RyRs [101]. The 
molecular determinants in Bcl-2 responsible for RyR binding were similar but not identical to the 
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ones responsible for IP3R binding [100]. While the BH4 domain of Bcl-2 was responsible for RyR 
binding, the Lys17 residue of Bcl-2 appeared dispensable for the interaction with RyRs. Also, the BH4 
domain of Bcl-2 was sufficient for inhibiting RyRs, overexpressed in HEK cells or endogenously 
present in rat hippocampal neurons. The binding of Bcl-2 to RyRs also appeared independent of its 
hydrophobic cleft, which is responsible for binding the BH3 domain of pro-apoptotic Bcl-2-family 
members [102]. The relevance of the RyR/Bcl-2 interaction for cancer cell survival ought to be further 
studied. Yet, recently, elevated RyR3 expression has been implicated in breast cancer risk [103]. 
Knocking down RyR3 in breast cancer cells impaired cell proliferation and migration. Furthermore, 
certain breast cancers host a signal nucleotide polymorphism in the 3’-UTR of the RyR3 gene, which 
prevented binding of a regulatory miRNA and caused elevated RyR3 expression in patient samples. 
Patients carrying the signal nucleotide polymorphism had a higher risk of developing breast cancer 
and its occurrence correlated to increased micro-calcification and poor progression-free survival. 
Also in breast cancer cells, a strong RyR2 upregulation has been described upon epithelial-
mesenchymal transition, a process that promotes invasive properties of cells and that is stimulated 
by hypoxia or epidermal growth factor [104]. However, the relevance of RyR/Bcl-2 complexes in 
breast cancer properties and their ability to undergo epithelial-mesenchymal transition remains to be 
further studied. 
 
Bcl-XL 
Bcl-XL is an anti-apoptotic protein related to Bcl-2. This proto-oncogene is expressed in many tissues 
[105]. At the mitochondria, Bcl-XL scaffolds and neutralizes pro-apoptotic Bcl-2-family members like 
Bak/Bax and BH3-only proteins Bim and Bid, thereby preventing MOMP and promoting cell survival 
[51]. Bcl-XL is frequently overexpressed in cancers by which apoptosis is inhibited and cell survival is 
promoted. High levels of Bcl-XL have been detected in advanced and relapsed multiple myeloma, 
prostate, rectal, small-cell lung, gastric, pancreatic cancer, and tongue carcinomas [106,107]. 
Furthermore, constitutive activation of the epidermal growth factor receptor in human glioblastoma 
cells increases the expression of Bcl-XL, resulting in apoptosis resistance [108]. Of interest, 
thrombocytopenia is a major side effect of inhibiting Bcl-XL in anti-cancer therapy, since Bcl-XL is 
essential to maintain platelet survival by restricting Bax activity [109]. Nevertheless, selective Bcl-XL 
inhibitors have been reported to be highly efficacious in combination with docetaxel to target a 
variety of solid tumors [110].  
Bcl-XL can directly bind the IP3R channel and regulate its single-channel Ca
2+ flux properties [76]. Bcl-
XL caused a potent sensitization of the IP3R, promoting its opening in response to very low [IP3] (10 
nM). At the molecular level, Bcl-XL bound all three IP3R isoforms by targeting a site located outside 
the first 600 amino acids of the IP3R1. Further experiments revealed that the C-terminal part of the 
IP3R between a.a. 2512 and 2750 contained a Bcl-XL-binding site (Fig. 5) [76]. Bcl-XL overexpression 
promoted IP3R-dependent Ca
2+ oscillations. Interestingly, purified tBid and Bax prevented Bcl-XL 
binding to IP3Rs and the sensitization of IP3R channels by Bcl-XL, suggesting an involvement of Bcl-
XL’s hydrophobic cleft in the regulation of IP3Rs. This was underpinned by follow-up work, indicating 
that the C-terminal site of the IP3R contains two domains reminiscent of BH3 domains, which may 
recruit Bcl-2/Bcl-XL via their hydrophobic cleft [111]. In DT40 cells, the decrease of steady-state ER 
Ca2+ levels and protection against strong B-cell receptor stimulation by overexpression of Bcl-XL 
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required the presence of IP3Rs (Fig. 2) [76]. Consistent with this, Bcl-XL promoted spontaneous Ca
2+ 
oscillations in wild-type but not in triple-IP3R-knockout (TKO) DT40 cells. As a consequence, Bcl-XL 
boosted mitochondrial bioenergetics in an IP3R-dependent manner, increasing nicotinamide adenine 
dinucleotide phosphate production (Fig. 4). Further work revealed that all three IP3R isoforms could 
enhance Bcl-XL’s anti-apoptotic properties [77], consistent with the fact that Bcl-XL can bind to all 
three IP3R isoforms [76] and can promote Ca
2+ oscillations mediated by IP3R1, IP3R2 or IP3R3 [77]. 
However, Bcl-XL only lowered the ER Ca2+-store content of IP3R3-, but neither of IP3R1- or IP3R2-
expressing TKO-DT40 cells. This suggested that lowering of the ER Ca2+-store content was not 
essential for the anti-apoptotic properties of Bcl-XL. Of note, similarly to Bcl-2, Bcl-XL too could 
directly bind to RyRs, which involved its BH4 domain and a Lys residue located in the BH3 domain 
[112]. Bcl-XL binding to RyRs suppressed Ca2+ release through the channels. The presence of these 
complexes in cancer cells and their relevance for oncogenic properties remain unknown. 
Besides IP3Rs and RyRs, Bcl-XL has been implicated in targeting Ca
2+-flux pathways of the 
mitochondria like VDAC1, although different outcomes have been reported with Bcl-XL inhibiting or 
stimulating VDAC1-mediated Ca2+ uptake into the mitochondria [113–115]. The inhibitory effect of 
Bcl-XL on VDAC1 could be attributed to its BH4 domain [116]. Of course, these effects of Bcl-XL on 
the rate of mitochondrial Ca2+ uptake could indirectly impact the ER Ca2+-release properties. For 
instance, decreased mitochondrial Ca2+ uptake, e.g. by Bcl-XL inhibiting VDAC1, may lead to an 
increase in cytosolic Ca2+ signaling for a given Ca2+ release from the ER. Furthermore, the inhibitory 
action of Bcl-XL on VDAC1 may be an additional mechanism to prevent toxic mitochondrial Ca2+ 
overload (Fig. 3). In contrast to these studies, Bcl-XL has also been reported to enhance VDAC1-
mediated mitochondrial Ca2+ uptake [114]. Although we and others [113,115,116] reported an 
inhibitory role for Bcl-XL on VDAC1, these data could reflect the dual role of VDAC1 in both mediating 
survival and apoptosis signaling [117]. As such, Bcl-XL may promote the transfer of pro-survival Ca2+ 
signaling while inhibiting pro-apoptotic Ca2+ signaling. Alternatively, differences in the experimental 
methods could account for this. For instance, many experiments performed by White et al. were 
based on mitochondrial Ca2+ uptake experiments in permeabilized cells where all VDAC1 channels 
across the mitochondrial outer membrane will participate in mitochondrial Ca2+ uptake [114]. In 
contrast, experiments in other studies relied on mitochondrial Ca2+ uptake measurements in intact 
cells exposed to agonists for which Ca2+ would be preferentially transferred via ER-mitochondrial 
contact sites [113,115,116]. Nevertheless, since a stimulatory effect of VDAC1 by Bcl-XL has never 
been shown in direct measurements based on purified VDAC1 channels, the molecular properties 
and the relevance of the VDAC1/Bcl-XL connection in promoting mitochondrial Ca2+ transfer ought to 
be further scrutinized. 
 
Mcl-1 
Mcl-1 is an anti-apoptotic member of the Bcl-2-protein family and has many important cellular 
functions. This proto-oncogene is crucial for the development and maintenance of several cell types 
including lymphocytes [118,119], neurons [120] and hematopoietic stem cells [121]. Additionally, 
Mcl-1 plays an important role in early embryogenesis [122]. The Mcl-1 protein has a very short half-
life and is structurally different from the other anti-apoptotic Bcl-2-family members [123]. The 
sequence of the putative BH4 domain of Mcl-1 substantially differs from the sequences of the BH4 
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domain of the Bcl-2 and Bcl-XL proteins. Furthermore, its N-terminus contains two PEST 
(proline/glutamic acid/serine/threonine-containing) regions, which affect the rate of turnover and 
contain several sites for phosphorylation [123]. Mcl-1’s pro-survival functions are advantageous to 
many types of cancer. Overexpression of Mcl-1 has been observed in hematopoietic and in lymphoid 
cancers as well as in solid tumors [123]. This is supported by an analysis of somatic copy-number 
alterations in different cancer types, showing that the gene encoding for Mcl-1 is frequently 
amplified in a broad spectrum of cancer cells [124]. Mcl-1 overexpression induces resistance to 
chemotherapeutic agents like paclitaxel and vincristine, but also to Bcl-2 inhibitors such as ABT-737, 
while the sensitivity of chemoresistant cells to these compounds can be restored after Mcl-1 
silencing [123,125]. 
One study reported the binding of Mcl-1 to IP3Rs [69]. It was shown that besides Bcl-2 and Bcl-XL, 
Mcl-1 too targeted the C-terminal tail of the IP3R (Fig. 5). All three Bcl-2-family members bound the 
IP3R domain with similar affinities. It was proposed that the last transmembrane domain of the IP3R 
was essential for these interactions. Mcl-1 enhanced IP3R-mediated Ca
2+ release, resulting in 
decreased steady-state ER Ca2+ levels (Fig. 2) [69]. Store depletion in Mcl-1-expressing cells became 
more prevalent in the presence of low [IP3], indicating that the sensitivity of IP3-dependent Ca
2+ 
release is enhanced by Mcl-1. The Mcl-1-mediated IP3R sensitization also contributes to low-level 
IP3R-mediated Ca
2+ signaling from the ER to the mitochondria and therefore stimulates mitochondrial 
bioenergetics (Fig. 4). Also, Mcl-1’s anti-apoptotic properties were promoted when IP3Rs were 
present in the DT40 cells [69]. Yet, the protective effect of Mcl-1 overexpression in IP3R-expressing 
DT40 cells was less pronounced than the effects observed for Bcl-2 or Bcl-XL overexpression.  
Of interest, Mcl-1 has recently been implicated to bind with high affinity to VDAC1, thereby 
stimulating VDAC1’s Ca2+-flux properties and thus increasing mitochondrial Ca2+ uptake, hence 
promoting ATP production (Fig. 4) [126]. Among all Bcl-2-family members, Mcl-1 was the strongest 
VDAC1-binding protein. The VDAC1/Mcl-1 complex appeared to be important for the survival of 
cancer cells, since the increase in mitochondrial [Ca2+] stimulates ROS production which in turn 
promotes cell migration [126]. In addition to this, Mcl-1 has recently been implicated in the control of 
mitochondrial dynamics by promoting Drp1-mediated mitochondrial fission and preventing 
mitochondrial hyperpolarization, which limits mitochondrial Ca2+ uptake [127]. 
 
Bok 
Bok, Bcl-2-related ovarian killer, is a multi-BH domain-containing pro-apoptotic protein that 
resembles Bax/Bak. It is scaffolded by Mcl-1 and Bfl-1, but not by Bcl-2 or Bcl-XL [128]. Although a 
first report suggested that Bok expression was restricted to reproductive tissues [128], Bok appears 
to be expressed in many tissues besides ovary with high levels in brain, lung, spleen and stomach 
[129]. Since Bok-knockout mice develop normally, it was proposed that the functions of Bok largely 
overlap with Bax/Bak or are only critical in certain conditions of cell stress [129]. Compared to 
Bax/Bak, the role of Bok in apoptosis is however much less characterized. A major portion of the 
endogenous Bok protein resides outside the mitochondria, including the ER, Golgi and nucleus [130]. 
Bok overexpression in cells resulted in apoptosis that required the presence of Bax/Bak proteins 
[130]. Bok overexpression caused a rapid disintegration and fragmentation of the ER and Golgi 
independently of downstream caspase 3 activation and apoptosis. ER/Golgi-targeting of Bok was 
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dependent on its C-terminal transmembrane domain. Cells lacking Bok displayed a normal sensitivity 
towards cell death stimuli like staurosporine and etoposide but displayed an increased sensitivity and 
abnormal ER-stress response to brefeldin A, a pro-apoptotic ER-stress inducer that disrupts ER-Golgi 
trafficking [130,131]. In further work, it was shown that Bok has an important function in mediating 
cell death upstream of Bax/Bak in response to ER stress, since Bok-deficient cells were protected 
against thapsigargin- or bortezomib-induced apoptosis [132]. The presence of Bok was essential for 
the activation of Bim, activating transcription factor 4 and CCAAT/enhancer-binding protein 
homologous protein, pro-apoptotic components of the unfolded protein response. The role of Bok in 
cancer is not fully understood, but deletions in the Bok gene were identified in high-resolution 
analyses of somatic copy-number alterations from more than 3000 cancer specimens as a frequent 
event to occur in different types of cancer [124]. However, in contrast to Bax deletion, which 
accelerated cancer development, Bok deletion did not accelerate the development of lymphomas in 
E-Myc transgenic mice [129]. 
Interestingly, among all Bcl-2-family members, Bok displayed the strongest binding to the IP3R [133]. 
Bok binding to IP3Rs was isoform-specific, since IP3R1 and IP3R2, but not IP3R3, were targets for Bok. 
IP3Rs may serve as a sink for Bok, as most of the cellular Bok was found in complex with IP3Rs. The 
domains responsible for IP3R1/Bok interaction were on the one hand a stretch of amino acids 
(PSRKKAKEP) located between a.a. 1895 and 1903 of IP3R1 (Fig. 5) and on the other hand a stretch of 
amino acids (LGREYV) located between a.a. 34 and 39, corresponding to a part of the N-terminal BH4 
domain of Bok. Furthermore, Bok-deficient cells displayed increased levels of IP3R1 and decreased 
IP3R2 and IP3R3 levels [133]. Yet, overall, Bok-expressing and Bok-deficient cells displayed similar IP3-
induced Ca2+ release (IICR) properties. Bok also did not cause major alterations in IP3R 
downregulation by the ubiquitin proteasome pathway and Bok was co-degraded with IP3R by this 
system in conditions of persistent activation of the IP3-dependent signaling pathway [133]. However, 
the association of Bok with the IP3R protected these channels from proteolytic digestion by 
chymotrypsin, which has a cleavage site in the IP3R in the proximity of the Bok-binding site [133]. Bok 
also protected IP3Rs against cleavage by caspase 3, an apoptosis executioner caspase, since Bok-
deficient cells exposed to apoptotic stimuli displayed a rapid cleavage of IP3Rs into an N-terminal 
170-kDa fragment and a C-terminal 95-kDa fragment containing the channel pore. This indicates that 
the Bok-expression levels may critically control the caspase 3-dependent cleavage of IP3Rs. This is 
particularly relevant in the context of the conflicting results on whether or not IP3Rs are bona fide 
substrates of caspase 3. About 15 years ago, the team of Mikoshiba reported that IP3R1 was a 
caspase 3 substrate as IP3R1 cleavage upon apoptotic stimuli was only observed in cells expressing 
caspase 3 [134]. Accordingly, a caspase 3-cleavage site (DEVD) was identified in IP3R1 (a.a. 1888-1892 
in mouse IP3R1) (Fig. 5). The removal of this site (by mutation) diminished Ca
2+ overload in DT40 cells 
and rendered them more resistant to apoptotic stimuli [135]. Furthermore, expression of the C-
terminal channel domain, an IP3R1 cleavage product, increased the tendency of these cells to 
undergo apoptosis. IP3R1 cleavage by caspase 3 was further shown to play an important role in 
apoptotic events that take place during mouse oocyte maturation [136,137]. However, other groups 
made observations contradicting the role of IP3R1 as a relevant caspase 3 substrate. For instance, 
Guillemette and co-workers showed that HeLa or Jurkat cells exposed to a variety of apoptotic 
stimuli with robust caspase 3 activation did not display cleavage of IP3R1 [138]. Here, recombinant 
caspase 3 also failed to cleave IP3R1 in the microsomal fraction. Consistent with this, Boehning and 
co-workers showed that the staurosporine-induced rise in cytosolic [Ca2+] in HeLa cells is 
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independent of caspase 3 expression or activity [139]. Also, IP3R1 cleavage did not occur in 
staurosporine-treated MCF7 cells re-complemented with caspase 3. These contradicting results raise 
the question whether differing endogenous Bok levels may account for the varying sensitivity of 
IP3R1 to caspase 3 cleavage in different cell models (e.g. DT40 cells versus HeLa or MCF7/caspase 3 
cells).  
 
Beclin 1 
Beclin 1 is an important regulator of autophagy, a catabolic pathway in which damaged organelles 
and macromolecules are degraded and recycled [140]. This protein is localized within cytoplasmic 
structures, such as the ER, mitochondria and the perinuclear membrane. Beclin 1 is critical to initiate 
autophagy since it is part of one of the main signal-initiating complexes, consisting of class III 
phosphatidylinositol 3-kinase/Vps34, Beclin 1 and p150 protein [141]. The Beclin 1 protein is 
composed of three main domains: (i) a BH3 domain located at the N-terminus (a.a. 114-123) that 
interacts with anti-apoptotic Bcl-2-family members, (ii) a central coiled-coil domain (a.a. 144-269) 
mediating Beclin 1 self-association and dimerization, and (iii) a C-terminal evolutionarily conserved 
domain (a.a. 244-337) that enables protein interactions and binds lipid membranes of cell organelles 
[140–143]. Via these domains Beclin 1 interacts with co-factors, including Vps34, PKB/Akt, Bif-1, Bcl-2 
and Bcl-XL, to positively regulate autophagy and initiate autophagosome formation [140]. Beclin 1 is 
a known tumor suppressor, since Beclin 1 haplodeficient mice display increased tumor formation 
[144]. Also, in ovarian, breast and prostate cancer, the tumor suppressive gene BECN1 was mono-
allelically deleted, whereas a decreased expression of Beclin 1 was observed in many types of cancer, 
including brain tumors and cervical cancer [140,141]. 
Several studies showed that IP3Rs are directly targeted by Beclin 1, which has a prominent binding 
site in the suppressor domain of the IP3R (a.a. 1-225) (Fig. 5) [145]. Originally, it was proposed that 
IP3R served as a scaffold for Beclin 1, thereby inhibiting autophagy by making it less available for its 
autophagy-inducing role in the Vps34 complex [146]. This complex mediates one of the earlier steps 
within the autophagy process downstream of mTOR/unc-51-like kinase 1 complex but preceding the 
autophagosome formation. As such, the IP3R served as a negative regulator of autophagy. In this 
context, Beclin 1 did not modulate IICR and thus IP3Rs rather served as a sink for Beclin 1, thereby 
limiting Beclin 1 availability for driving the autophagy process. Further work actually found an 
autophagy-promoting role for the IP3R/Beclin 1 complex [145]. Beclin 1 binding to the IP3R occurred 
in a dynamic manner during starvation-induced autophagy, leading, together with an increased ER 
Ca2+-store content, to a sensitization of agonist-induced Ca2+ signaling. Cells lacking Beclin 1 failed to 
display enhanced IP3R-mediated Ca
2+ signaling. This involved a direct sensitization of the IP3R by 
Beclin 1, since purified Beclin 1 enhanced IICR in permeabilized cells. IP3R sensitization and 
subsequent Ca2+ signaling were essential to drive starvation-induced autophagic flux, since 
pharmacological IP3R inhibition and intracellular Ca
2+ buffering prevented starvation-induced 
autophagy [145]. Yet, at this point it is not clear whether IP3Rs and Ca
2+ signaling are involved in 
Beclin 1’s function as a tumor suppressor. 
 
PKB/Akt and PTEN 
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The phosphoinositide 3-kinase (PI3K)/protein kinase B (PKB)/Akt signaling pathway is a tightly 
controlled process regulating cell survival, proliferation and cell death [147,148]. PI3K, a lipid kinase, 
converts phosphatidylinositol 4,5-bisphosphate (PIP2) into phosphatidylinositol 3,4,5-trisphosphate 
(PIP3) after it is activated by G-protein-coupled receptors and receptor tyrosine kinases [147,149]. 
Next, PIP3 recruits phosphatidylinositol-dependent kinase 1 (PDK1) and PKB/Akt, a serine/threonine 
kinase, to the plasma membrane. This leads to PKB/Akt activation through phosphorylation of T308 
by PDK1 and S473 by mTORC2. Subsequently, active PKB/Akt phosphorylates its substrates in the 
cytoplasm and nucleus, thereby regulating several cellular functions, including cell growth, 
proliferation, survival, metabolism, protein synthesis and apoptosis [147]. There are three Akt 
isoforms, Akt1, Akt2 and Akt3, which are structurally highly homologous but exhibit different 
functions [150]. Akt1 and Akt2 are ubiquitously expressed, whereas Akt3 expression is restricted to a 
few tissues. Phosphatase and tensin homolog deleted on chromosome 10 (PTEN), a lipid and protein 
phosphatase, is the most important negative regulator of the PI3K/Akt signaling pathway [149]. Via 
its lipid phosphatase activity, PTEN reverses the action of PI3K by dephosphorylating PIP3 to PIP2, 
counteracting all downstream functions controlled by PKB/Akt. The protein phosphatase activity of 
PTEN is used to inhibit cell migration and cell cycle arrest [149]. The tumor suppressive activity of 
PTEN is lost in many human tumors, such as breast, thyroid, kidney, colorectal and prostate cancer 
[124,149]. Somatic mutations, gene silencing or epigenetic mechanisms cause this loss of functional 
PTEN in tumor cells. Hyperactivity of PKB/Akt, caused by mutations in the catalytic subunit or 
amplification of Akt, has also been observed in several cancer types [150]. For example, Akt1 
amplification has been detected in gastric carcinomas, whereas amplification of Akt2 occurred in 
ovarian, breast, colorectal and pancreatic cancers. In several tumor types, including breast, 
colorectal, ovarian, lung and bladder cancer, an activating mutation on Akt1 (E17K), which results in 
constitutive localization of Akt at the plasma membrane and promotes growth factor-independent 
phosphorylation of T308 and S473, has been observed [150]. 
Over the past years, several studies reported the interaction of Akt kinase with IP3Rs at the ER. 
Joseph and co-workers showed that phosphorylation of the IP3R by PKB/Akt occurred in vivo [151]. 
All three IP3R isoforms contain a consensus substrate motif for PKB/Akt kinase (RXRXX(S/T)) located 
in the cytosol-exposed C-terminal tail (Fig. 5). Upon Akt activation by insulin, endogenous IP3Rs 
present in CHO-T cells were phosphorylated [151]. A prostate cancer cell line with constitutively 
active Akt due to loss of functional PTEN (LnCAP cells) exhibited constitutive phosphorylation of 
endogenous IP3R1 as well. Exposure to a PI3K inhibitor removed IP3R phosphorylation in the two 
aforementioned cell lines. In COS cells transfected with constitutively active Akt, IP3R 
phosphorylation was inhibited by mutating a serine amino acid residue present in the Akt substrate 
motif of the IP3R (S2681A and S2681E). IP3R channel function was not directly modified by Akt 
phosphorylation, as IICR was comparable between wild-type, non-phosphorylatable S2681A mutant 
and phosphomimic S2681E mutant IP3Rs expressed in COS cells [151]. Nevertheless, caspase 3 
activation, induced by staurosporine, was enhanced in TKO-DT40 cells expressing the S2681A mutant 
compared with cells expressing wild-type IP3Rs or IP3R mutants with a mimicked effect of Akt 
phosphorylation (S2681E). In contrast, other studies did report reduced Ca2+ release from IP3Rs 
phosphorylated by PKB/Akt [152,153]. It was shown that phosphorylation of IP3Rs, induced by 
overexpressing constitutively active PKB/Akt, inhibited IICR and histamine-induced Ca2+ release, 
whereas the ER Ca2+ content was not decreased [152]. In this study, a greater ATP-induced Ca2+ 
response was observed in COS cells expressing mutant IP3R
S2681A compared to cells expressing wild-
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type IP3R. The former were also more sensitive to apoptotic stimuli like menadione and displayed 
higher mitochondrial Ca2+ rises in response to these stimuli. Also, glioblastoma cells exhibiting Akt 
hyperactivity due to loss of PTEN showed reduced IICR, menadione-induced mitochondrial Ca2+ 
uptake and apoptosis compared with glioblastoma cells re-expressing PTEN [152]. These results 
indicate that phosphorylation of IP3Rs by active PKB/Akt reduces Ca
2+ release from the ER and 
subsequent Ca2+ transfer to the mitochondria, leading to the protection of cells from apoptotic 
stimuli (Fig. 3). Another independent study reported that agonist-induced Ca2+ release from the ER 
and the subsequent mitochondrial Ca2+ rise is reduced by expressing constitutively active Akt1 in 
HeLa cells, thereby protecting cells from apoptotic stimuli that act through mitochondrial Ca2+ 
overload like H2O2 [153]. This study elegantly showed that Akt modulated IP3R activity, resulting in an 
inhibition of agonist-induced Ca2+ release and protection from Ca2+-mediated apoptotic stimuli. In 
further work it was demonstrated that Akt reduces ER-mitochondrial Ca2+ transfer and protects 
against apoptosis by specifically acting on IP3R3 [154]. Activated Akt suppressed IICR and apoptosis, 
induced by arachidonic acid, in COS7 cells, which lack detectable IP3R1, but not in IP3R3-deficient SH-
SY5Y cells. However, Akt did reduce Ca2+ release and did protect against apoptotic stimuli in SH-SY5Y 
cells expressing IP3R3. Interestingly, it has been proposed that pro-apoptotic ER-mitochondrial Ca
2+ 
transfers preferentially occur via IP3R3 [155,156], although a pivotal role of IP3R1 in Ca
2+-mediated 
apoptotic cell death was reported in other studies as well [135,157].  
Recently, tumor suppressor PTEN was found to be localized at the ER and MAMs and to modulate 
Ca2+ transfer from the ER to mitochondria in a protein phosphatase-dependent manner [158]. PTEN 
silencing, which leads to increased phosphorylation and activity of Akt, impaired the release of Ca2+ 
from the ER and lowered cytosolic and mitochondrial Ca2+ transients in response to agonists [158]. 
Consequently, sensitivity to arachidonic acid, an apoptotic inducer causing ER Ca2+ release, and 
subsequent mitochondrial Ca2+ overload were decreased in PTEN-silenced cells, but were both 
increased upon overexpression of PTEN that is targeted to the ER, indicating that ER-localized PTEN 
sensitizes cells to Ca2+-mediated apoptotic stimuli (Fig. 3). Moreover, initiation of Ca2+-dependent 
apoptosis with arachidonic acid enriched PTEN localization at the ER. Co-immunoprecipitation 
experiments revealed that PTEN interacts with IP3R3 [158]. Finally, it was determined that ER-
localized PTEN directly reduces the Akt-dependent phosphorylation state of the IP3R through its 
protein phosphatase activity, hence modulating Ca2+ release from the ER and cellular sensitivity to 
Ca2+-mediated apoptotic stimuli (Fig. 5). 
 
Promyelocytic leukemia protein (PML) 
The promyelocytic leukemia protein (PML) is an important tumor suppressor, which controls various 
cellular functions, including apoptosis, DNA-damage response, cellular proliferation and senescence 
[159,160]. The PML gene was identified through its location at the breakpoint of the t(15;17) 
chromosomal translocation, which is often observed in acute promyelocytic leukemia [160]. As a 
result of this translocation, the PML gene is juxtaposed to the gene encoding the retinoic acid 
receptor alpha, which leads to the formation of fusion proteins that hinder the differentiation of 
hematopoietic cells. At the structural level, the N-terminal part of the PML protein is highly 
structured, in contrast to its C-terminus, and contains a RING domain, which is a zinc-finger that 
exhibits E3 ligase activity, two additional zinc-finger motifs called B-boxes and an alpha-helical coiled-
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coil domain [160,161]. These N-terminal domains are responsible for the oligomerization of PML and 
they mediate protein-protein interactions, allowing PML to concentrate in nuclear bodies. To exert 
its tumor suppressive function, PML interacts with a large number of proteins, including sumoylated 
PML, p53, protein phosphatase 2A (PP2A) and PKB/Akt [160,161]. PML expression is lost or reduced 
in hematopoietic malignancies as well as in solid tumors, such as colon, lung, prostate and breast 
cancers [160]. Interestingly, PML-knockout mice and primary cells lacking PML are protected from 
apoptosis triggered by a variety of stimuli [162]. 
A few years ago, extra-nuclear PML was discovered to be localized to the ER and MAMs and to 
regulate apoptosis at the ER by modulating Ca2+ release [163]. Cytosolic and mitochondrial Ca2+ 
responses induced by agonists or oxidative apoptotic stimuli were higher in cells expressing PML than 
in cells lacking PML. Consistently, the presence of PML in cells was protective against ER stress-
induced apoptosis [163]. Interestingly, the dampened Ca2+ responses observed in PML-deficient cells 
could be fully restored by ER-targeted PML [163]. As a consequence, these cells regained sensitivity 
to ER stress-induced apoptosis, but remained resistant to etoposide, an apoptotic inducer that acts 
independently of Ca2+. These functional observations could be linked to a physical interaction 
between PML and IP3R3 [163]. Moreover, the levels of phosphorylated IP3R3 were higher in PML
-/- 
than in PML+/+ MEFs cells due to higher amounts of phosphorylated, active Akt and reduced amounts 
of protein phosphatase PP2A associated with IP3R3 in the former [163]. Hence, the tumor suppressor 
PML was found to be essential to recruit PP2A to IP3R3-Akt complexes at the MAMs (Fig. 3), where 
PP2A counteracts Akt activity, thereby suppressing Akt-mediated phosphorylation of the IP3R3 (Fig. 
5). As a consequence, IP3R3-mediated Ca
2+ transfer from the ER into the mitochondria and, 
eventually, apoptosis are promoted in PML-expressing cells [161,163]. Thus, similarly to PTEN, PML 
stimulates pro-apoptotic Ca2+ signaling events by negatively regulating the activity of Akt at the ER. 
 
Breast and ovarian cancer susceptibility gene 1 (BRCA1) 
Tumor suppressor BRCA1 is a chromatin-interacting protein that has a critical role in homologous 
recombination repair of double-strand DNA breaks [164]. Its main function is to preserve genomic 
integrity, although growing evidence indicates that BRCA1 activity is necessary for mammary 
epithelial differentiation as well [164]. Breast and ovarian cancer are frequently associated with 
impaired functioning of BRCA1, caused by BRCA1 mutations, loss of expression or BRCA1 
downregulation. BRCA1 mutations predispose to breast and ovarian cancer, although it is still not 
clear why this predisposition exists since this tumor suppressor is expressed in all cells. In families 
with hereditary breast and ovarian cancer, the N-terminal RING domain and the C-terminal BRCT 
repeats of BRCA1 are frequently mutated [164]. These two domains contribute to the tumor 
suppressive activity of BRCA1. The N-terminal RING domain exhibits E3 ubiquitin ligase activity when 
heterodimerized with BARD1, another RING- and BRCT domain-containing protein [164,165]. The 
BRCT repeats are needed to concentrate BRCA1 in subnuclear repair foci that appear after DNA 
damage. These repeats are phosphopeptide-binding domains responsible for the interaction of 
BRCA1 with partner proteins like the endonuclease CtIP [166], the adaptor protein Abraxas [167] and 
the DNA helicase BRIP1 [168]. Through their interaction with BRCA1, these partner proteins regulate 
DNA repair and maintain genome stability. 
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Recently, BRCA1 was identified as a novel binding partner of the IP3R1 [169]. A major subpopulation 
of the BRCA1 pool localized outside the nucleus, residing at ER membranes by binding phospholipids. 
Full-length IP3R/BRCA1 complexes were identified. The complex was formed through a direct 
interaction of the C-terminal tail of the IP3R1 with the N-terminal domain of the BRCA1 protein (a.a. 
1-112, the so-called RING domain) (Fig. 5). BRCA1 overexpression caused an increase in IP3R-
mediated Ca2+ signaling in intact HeLa cells, particularly sensitizing cells towards low [agonist] [169]. 
This was due to a direct sensitization of IP3R channels by BRCA1 via its RING domain, which was 
sufficient by itself to increase IP3R single-channel activity (Fig. 3). FRET studies revealed that the 
IP3R1/BRCA1-protein complex was dynamically formed during paclitaxel-induced apoptosis [169]. 
Furthermore, in an ovarian cancer cell line paclitaxel-induced cytosolic Ca2+ rise and apoptotic 
susceptibility were critically dependent on the BRCA1-expression status. Comparison of wild-type 
versus TKO-DT40 cells revealed that the recruitment of BRCA1 to the ER membranes increased in an 
IP3R-dependent manner during apoptosis [169]. However, also other mechanisms appeared to 
contribute to the recruitment of BRCA1 to ER membranes, likely involving the C-terminal domain of 
BRCA1 (the BRCT repeats), which displayed an intrinsic lipid-binding property [169]. The BRCT 
repeats, but not the N-terminal RING domain, bound several ER-resident phospholipids, including 
phosphatidic acid and PIP2. Further studies will be needed to determine whether BRCA1’s pro-
apoptotic function is dependent on the presence of the IP3R, e.g. by comparing the effect of BRCA1 
overexpression in wild-type versus TKO-DT40 cells. 
 
p53 
The transcription factor p53 is one of the most important tumor suppressor proteins in the cell. The 
p53 protein transcriptionally regulates its downstream target genes, preventing tumorigenesis [170]. 
Multiple biological processes are regulated by p53, including cell cycle arrest, apoptosis, senescence, 
DNA repair and energy metabolism [171]. In unstressed cells, the level of p53 is kept low through 
proteasomal degradation of the protein. In response to stress signals, such as DNA damage, hypoxia 
and oncogene activation, p53 is stabilized principally through post-translational modifications, 
leading to p53 activation and accumulation in the cell. Consequently, activated p53 regulates the 
expression of its target genes by binding to a specific degenerate DNA sequence, known as the p53-
responsive element. In approximately 50% of all human tumors and in almost every type of cancer, 
including leukemia, lung, colorectal, cervical and ovarian cancer, p53 mutations, which are mainly 
missense mutations, occur [170–172]. These mutant p53 proteins either lose the tumor suppressive 
functions of wild-type p53 or acquire new oncogenic activities that are independent of wild-type p53, 
such as promoting angiogenesis, metastasis and tumor cell proliferation [170].  
A recent study revealed a novel, non-transcriptional role for cytosolic p53 at the level of the ER 
[173,174]. Under untreated conditions p53 was found to localize at the ER, the MAMs and the 
cytosol [173]. After p53 induction in response to stress, elicited by chemotherapeutics like 
adriamycin or oxidative stress like H2O2, p53 accumulated at the ER and the MAMs. Furthermore, 
apoptotic cell death, triggered by H202, was enhanced after adriamycin-induced p53 accumulation at 
the ER and the MAMs [173]. This correlated to an altered regulation of Ca2+ homeostasis after p53 
induction at the ER/MAM compartments. The elevated ER Ca2+ levels and agonist-induced Ca2+ 
release by adriamycin was critically dependent on the cellular presence of p53 and promoted 
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apoptosis. Using pharmacological compounds inhibiting p53’s transcriptional function and p53-
targeted chimeras (p53-∆NLS and ER-p53), it was excluded that the p53-dependent modulation on 
Ca2+ homeostasis was caused by a transcriptional role of p53 [173]. Instead, p53 modulated Ca2+ 
homeostasis and apoptosis through an interaction of its C-terminal regulatory domain with the 
SERCA pump at the ER. In cells overexpressing wild-type p53, the rate of Ca2+ accumulation in the ER 
increased proportionally with the induction of p53 by adriamycin, indicating that p53 promoted 
SERCA activity. Interestingly, oncogenic p53 mutants failed to stimulate SERCA activity. The 
underlying molecular mechanism involved the lowering of the oxidation state of SERCA upon p53 
activation, leading to increased Ca2+ loading of the ER (Fig. 2) [173]. As a consequence, Ca2+ transfer 
from the ER to the mitochondria is boosted, resulting in a higher level of mitochondrial Ca2+ overload 
and apoptotic cell death. The interplay between p53 and Ca2+ signaling is not limited to 
chemotherapy but is also an inherent part of the cellular response of cancer cells exposed to 
photodynamic therapy (PDT) [175]. In MEF cells, PDT transiently increased the cytosolic and 
mitochondrial [Ca2+] in a p53-dependent manner. Consequently, p53-/- MEFs were more resistant to 
apoptosis triggered by PDT compared with the p53+/+ clone. This indicates that p53 is required to 
regulate the efficacy of apoptotic Ca2+ signals in vitro, suggesting that cancer cells can become 
resistant to PDT by mutation or loss of p53. These concepts were also validated by in vivo Ca2+ 
signaling and cell death measurements in three-dimensional tumor masses [175]. PDT triggered 
higher cytosolic Ca2+ responses in p53+/+ than in p53-/- xenografted tumors, indicating that functional 
p53 is needed to generate an efficient Ca2+ response after PDT to trigger apoptotic cell death in 
tumor cells. Moreover, the sensitivity to PDT-triggered apoptosis was reduced in tumor masses 
expressing p53 by buffering intracellular Ca2+ [175]. Oppositely, the PDT-induced Ca2+ response and 
apoptosis in p53-deficient cells could be restored by overexpressing either MCU or SERCA. Hence, 
both in vitro and in vivo, extra-nuclear p53 promotes pro-apoptotic Ca2+ signaling that originates at 
the ER, thereby determining the sensitivity of tumor cells to PDT. 
Furthermore, these studies also provide novel insights in the mechanisms that underlie the poor 
responses of cancer cells deficient in p53 to chemotherapy or PDT [176,177], linking the absence of 
p53 to a failure to cause pro-apoptotic Ca2+ transmission from ER to mitochondria and to kill cancer 
cells. Hence, boosting the efficiency of ER-mitochondrial Ca2+ transfer may therefore offer a potential 
strategy to enhance the responses of cancer cells to chemo- and photo-therapeutic treatments 
[176,177].  
 
Ras 
Ras is a small GTPase that regulates various intracellular signaling pathways, thereby controlling cell 
growth, differentiation and survival [178,179]. There are three Ras isoforms, K-Ras, N-Ras and H-Ras, 
which are extremely homologous to one another. The Ras protein, anchored to the inner leaflet of 
the plasma membrane, is activated by cell surface receptors, including G-protein-coupled receptors 
and receptor tyrosine kinases, which induce guanine nucleotide exchange factors to interchange GDP 
with GTP on Ras [179,180]. Ras activity is kept under control by GTPase-activating proteins (GAPs), 
which inactivate Ras by enabling its GTPase activity, resulting in the hydrolysis of GTP. Active Ras 
controls cell fate via many downstream effectors, such as Raf, PLCε and PI3Ks [179]. The oncogene 
Ras is mutated in 33% of human cancers, including pancreatic, colorectal and lung cancer [180]. Due 
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to mutational activation, Ras becomes constitutively active by binding GTP in an unregulated manner 
instead of switching between the active and inactive states like wild-type Ras. Especially mutations of 
a.a. 12, 13 or 61 render Ras insensitive to GAP activity and reduce the intrinsic GTPase activity. 
Oncogenic Ras has been implicated in regulating IP3Rs and Ca
2+ signaling. Earlier work indicated that 
Ras could enhance agonist-induced Ca2+ signaling in fibroblasts and other cell types upon Ras 
transformation [181]. This may be linked to the ability of Ras to directly interact with PLCε when GTP 
analogues were present [182]. PLCε appeared to be recruited to the plasma membrane in a Ras-
dependent manner, resulting in an increased enzyme activity responsible for PIP2 hydrolysis and the 
production of IP3. Ras could in vitro not induce an increase in PLCε activity, indicating that Ras may 
stimulate PLCε by causing its translocation to the plasma membrane. Further molecular studies 
revealed a prominent role for the Ras-associating domain 2 (RA2), but not RA1, within the PLCε 
structure for the regulation by Ras [183]. Interaction of Ras with the RA2 domain of PLCε enabled its 
translocation to the plasma membrane and altered its conformation from an auto-inhibited state 
into an active state in which PIP2 is available to the catalytic site, resulting in PIP2 hydrolysis and IP3 
production. 
Besides targeting IP3-producing enzymes, Ras has also been implicated in altering IP3R-expression 
profiles. This was shown in a study comparing two isogenic colorectal cancer cell lines: one cell line 
expressing oncogenic mutant K-RasG13D and one cell line expressing wild-type K-Ras [184]. Cells 
expressing K-RasG13D displayed a decrease in agonist-induced Ca2+ signaling, while silencing of Ras in 
these cells enhanced agonist-induced Ca2+ signaling [184]. This effect appeared to be a direct effect 
on the IP3R, since a membrane-permeable variant of IP3 had similar effects as agonists that indirectly 
lead to an increase in the intracellular IP3 levels. The remodeling of IP3-induced Ca
2+ signaling by K-
RasG13D occurred at the level of the ER, since K-RasG13D-expressing cells displayed a decrease in ER 
Ca2+-store content [184]. This correlated with alterations in the expression levels of key ER Ca2+-
transport systems, in which K-RasG13D-expressing cells expressed lower SERCA2b and IP3R3 levels but 
considerably higher IP3R1 levels. Thus, a decreased ER Ca
2+ uptake by SERCA2b downregulation and 
an increase in ER Ca2+ leak by IP3R1 upregulation may account for the decrease in steady state ER Ca
2+ 
levels in these cells (Fig. 2). Furthermore, IP3R3 has been proposed as a pro-apoptotic factor by 
specifically mediating the transfer of pro-apoptotic Ca2+ signals from the ER into the mitochondria, 
resulting in mitochondrial Ca2+ overload [156]. In any case, both the decreased ER Ca2+ levels and the 
decreased IP3R3-expression levels, would be protective mechanisms preventing mitochondrial Ca
2+ 
overload and favoring apoptosis resistance. This is backed up by experiments showing that K-RasG13D 
cells displayed reduced mitochondrial Ca2+ signals in response to agonists and an increased resistance 
towards apoptotic stimuli [184]. In summary, this study convincingly shows that Ras not only impacts 
Ca2+ signaling at the level of IP3-producing enzymes but also directly at the level of the ER by 
remodeling the expression of IP3R isoforms and SERCA2b. As such, oncogenic mutations in K-Ras may 
favor survival of cancer cells by dampening ER-originating Ca2+ signaling events that stimulate the 
apoptotic sensitivity of cells, promoting malignant cell survival. 
In addition to this, it is known that protein kinase C (PKC)-mediated phosphorylation of K-Ras4B 
causes its translocation from the plasma membrane to the intracellular environment, including the 
ER membranes, and limits cell survival [185]. A recent study revealed that Ras can impact cell survival 
by targeting the IP3R at the ER [186]. Strikingly, cell lines expressing wild-type K-Ras were sensitive to 
PKC agonists, while cell lines expressing the K-RasG13D mutant were much more resistant to this 
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treatment. A phosphomimetic mutant of activated K-Ras could bind the C-terminus of the IP3R1 with 
much greater efficiency than activated K-Ras or the phosphorylation dead mutant of activated K-Ras 
[186]. Furthermore, recombinant Bcl-XL enhanced the binding of the phosphomimetic K-Ras variant 
to the C-terminus of the IP3R1. Also endogenously activated K-Ras interacted with IP3R3, a 
phenomenon enhanced by PKC agonists. Interestingly, at the IP3R3 single-channel level, purified 
activated phosphomimetic K-Ras, but not the activated phosphodead K-Ras, counteracted the 
sensitization of IP3Rs by purified Bcl-XL (Fig. 5) [186]. In intact cells, overexpression of activated K-Ras 
suppressed mitochondrial Ca2+ dynamics, a phenomenon aggravated when overexpressing activated 
phosphomimetic K-Ras (Fig. 4). The impact of this K-Ras overexpression on mitochondrial Ca2+ was 
strictly dependent on Bcl-XL, since overexpression in Bcl-XL-knockout cells was without effect [186]. 
This impacted cell survival and death processes, like autophagy. Hence, overexpression of activated 
phosphomimetic K-Ras or exposing cancer cells that express endogenously activated K-Ras to PKC 
activators resulted in cell death and increased autophagosome punctae formation. This depended on 
the presence of Bcl-XL, since Bcl-XL-deficient cells were resistant to activated phosphomimetic K-Ras 
overexpression [186]. This autophagy stimulation appeared to promote cell death, since cells lacking 
the essential autophagy gene ATG5 were partially protected against phosphomimetic K-Ras 
overexpression, supporting the concept that excessive autophagy activation can result in cell death. 
Interestingly, a recent study illustrated a direct link between Ca2+ regulation and another oncogenic 
form of Ras: the oncogenic H-Ras (H-Ras12v). H-Ras localizes at the MAMs and regulates the 
transmission of Ca2+ from the ER to mitochondria, thereby inhibiting apoptosis and in turn promoting 
cellular transformation [187]. 
To summarize, K-Ras and its oncogenic forms can alter cell survival by modulating the properties of 
the ER Ca2+ stores, lowering the ER Ca2+-store content and IP3R3 levels, two protective mechanisms 
implicated in apoptosis resistance. In addition, phosphorylation of K-Ras results in cell death by 
suppressing pro-survival Ca2+-signaling events in the mitochondria and triggering excessive 
autophagy as a cell-death mechanism. 
 
Conclusions 
A growing list of tumor suppressors and oncogenes that have additional roles in the regulation of ER 
Ca2+ handling have been identified. These functions appear to be critical for their biological activity of 
controlling cell death and survival. At the level of the ER, tumor suppressors and oncogenes impact 
Ca2+ homeostasis (e.g. ER Ca2+-store content) and/or Ca2+ dynamics (e.g. Ca2+ release from the ER), 
thereby facilitating or preventing mitochondrial Ca2+ overload, respectively. In many cancers, in 
which these tumor suppressors and oncogenes are dysregulated, Ca2+ homeostasis and dynamics are 
altered in such a way that cells fail to induce pro-apoptotic Ca2+ signaling events that lead to 
mitochondrial Ca2+ overload. As a consequence, in these cancer cells apoptosis is, at least partly, 
avoided by an altered Ca2+ signaling, which favors persistent survival despite on-going cell stress and 
damage. Restoring proper Ca2+ signaling could therefore be a promising avenue for re-sensitizing 
cancer cells to their intrinsic pro-apoptotic signaling mechanisms and to therapeutic interventions 
like chemotherapy and PDT. 
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Legends figures 
Fig. 1: ER-mitochondrial Ca2+ signaling in healthy cells and in cancer cells. Oncogenes are indicated 
in green, whereas tumor suppressors are depicted in red. Bar-headed lines indicate an inhibitory 
interaction. Arrow-headed lines indicate a stimulatory interaction. The black arrows represent Ca2+ 
fluxes. The level of shading of the ER corresponds to the ER [Ca2+], i.e. a darker shade indicates a 
higher [Ca2+] while lighter shades represent lower Ca2+ levels. Left Panel, In normal, healthy cells, 
tumor suppressors (PTEN, BRCA1, Beclin 1, and p53) and oncogenes (Bcl-2-family members, PKB/Akt, 
and Ras) are in balance, thereby providing proper Ca2+ transfer from the ER to the mitochondria. This 
Ca2+ flux ensures cell survival by driving mitochondrial bioenergetics. SERCA pumps cytosolic Ca2+ into 
the ER lumen, whereas Ca2+ is released from the ER by the IP3R. Ca
2+ released from the ER is taken up 
by the mitochondria via VDAC1, present in the outer mitochondrial membrane, and MCU, located in 
the inner mitochondrial membrane. Right Panel, Alterations to the ER-mitochondrial Ca2+-signaling 
pathway can render cancer cells resistant to cell death stimuli. Upregulation of oncogenes, such as 
Bcl-2, and/or downregulation of tumor suppressors, like p53, prevent the occurrence of toxic pro-
apoptotic ER-mitochondrial Ca2+ fluxes. 
Fig. 2: Indirect modulation of the Ca2+-mediated cell death response in damaged healthy or 
damaged cancer cells by tumor suppressors and oncogenes. Symbols and colors are as explained in 
the legend of figure 1. Left Panel, Pro-apoptotic ER-mitochondrial Ca2+ signaling events can be 
modulated indirectly by altering the ER Ca2+-store content. Tumor suppressor p53 is upregulated in 
healthy cells that became damaged due to various stress conditions, such as the presence of toxic 
compounds or DNA damage. Upregulation of p53, which stimulates SERCA activity and therefore 
results in an increase of the ER Ca2+ content, boosts excessive Ca2+ transfers from the ER to the 
mitochondria and subsequently leads to mitochondrial Ca2+ overload and apoptotic cell death. Right 
Panel, Ca2+-mediated cell death can be circumvented in stressed cancer cells by a decreased ER Ca2+ 
content, which indirectly prevents mitochondrial Ca2+ overload. Oncogenes Bcl-2 and Ras can 
decrease the ER store content by inhibiting the SERCA pump or by lowering SERCA2b expression 
levels respectively. Bcl-XL, Mcl-1 and Bcl-2 can also sensitize IP3Rs located in parts of the ER 
membrane outside of the MAMs to low levels of IP3 signaling, promoting basal ER Ca
2+ leak. This will 
lower the ER Ca2+ levels and prevent cell death caused by mitochondrial Ca2+ overload.  
Fig. 3: Direct modulation of the Ca2+-mediated cell death response in stressed healthy or stressed 
cancer cells by tumor suppressors and oncogenes. Symbols and colors are as explained in the legend 
of figure 1. Left Panel, Apoptotic cell death is stimulated in damaged healthy cells by directly 
modulating IP3R-mediated Ca
2+ signaling events. Tumor suppressors PTEN, PML and BRCA1 increase 
IP3R activity, thereby facilitating mitochondrial Ca
2+ overload. In contrast to PTEN and BRCA1, PML 
appears to act indirectly on the IP3R by facilitating the recruitment of PP2A, which counteracts the 
apoptosis-suppressing effects of PKB/Akt on the IP3Rs. Right Panel, Upregulated levels of oncogenes 
that reduce toxic ER-mitochondrial Ca2+ transfers can cause malignant cells to survive stress 
conditions, like stress induced by anti-cancer therapies. Bcl-2 as well as PKB/Akt suppress excessive, 
pro-apoptotic Ca2+ signaling events by directly inhibiting IP3R activity. Bcl-XL inhibits VDAC1-mediated 
Ca2+ uptake into the mitochondria, hence preventing mitochondrial Ca2+ overload.  
Fig. 4: Regulation of mitochondrial bioenergetics by oncogenes and tumor suppressors. Symbols 
and colors are as explained in the legend of figure 1. Left Panel, Mitochondrial energy production is 
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maintained by constitutive low-level IP3R-mediated Ca
2+ transfer from the ER to the mitochondria, 
boosting ATP production. Low-level IP3R-mediated Ca
2+ signaling is stimulated by Mcl-1, Bcl-2 and 
Bcl-XL, which sensitize the IP3Rs present in the MAMs to basal IP3 levels. Mcl-1 also increases 
mitochondrial Ca2+ uptake by stimulating VDAC1’s Ca2+-flux properties. Right Panel, Phosphorylated 
K-Ras4B suppresses mitochondrial Ca2+ dynamics by counteracting the sensitization of IP3Rs by Bcl-
XL, thereby suppressing mitochondrial metabolism and triggering autophagic cell death. 
Fig. 5: Linear representation of the IP3R isoform 1 and its regulation by tumor suppressors and 
oncogenes. Oncogenes are represented in green, while tumor suppressors are indicated in red. Bar-
headed lines indicate an inhibitory interaction. Arrow-headed lines indicate a stimulatory interaction. 
Interactions with the IP3R without functional effect are represented by oval arrows. The IP3R1 
consists of three large functional domains: a ligand-binding domain, which is composed of a 
suppressor domain and an IP3-binding core, a modulatory and transducing domain, and a C-terminal 
channel region that contains six transmembrane domains indicated as black bars. Beclin 1 binds to 
the N-terminus of IP3R1 (suppressor domain), causing IP3R sensitization that is required for driving 
mTOR-dependent autophagic flux. Bcl-2 inhibits IP3R activity by binding with its N-terminal BH4 
domain to a.a. 1389-1408 in the mouse IP3R1 (green region of IP3R1), located in the central, 
modulatory domain of the channel. Bok interacts with a.a. 1895-1903 (indicated as the red region) of 
the IP3R. Through this interaction, Bok protects the channel from caspase 3-dependent cleavage by 
shielding a caspase 3-cleavage site (DEVD) that was identified at a.a. 1888-1892 in the mouse IP3R1. 
Interaction of Bcl-2, Bcl-XL and Mcl-1 with the C-terminal region of the IP3R (a.a. 2570-2749) appears 
to be dependent on the sixth transmembrane domain of the receptor, which results in sensitization 
of the channel to basal IP3 levels. Phosphorylated K-Ras4B directly binds to the IP3R (a.a. 2591-2734), 
and this binding is promoted in presence of Bcl-XL. Phosphorylated K-Ras4B counteracts the 
sensitization of IP3R by Bcl-XL, thereby suppressing mitochondrial Ca
2+ dynamics. In the absence of 
Bcl-XL, phosphorylated K-Ras4B mildly sensitizes the IP3R to low [IP3]. PKB/Akt suppresses IICR by 
phosphorylating S2681 in the C-terminal part of the IP3R. In contrast, the Akt-mediated IP3R 
inhibition is counteracted by PTEN, which dephosphorylates the IP3R at S2681 via its protein 
phosphatase activity. Also, PML inhibits Akt-mediated phosphorylation of the IP3R by recruiting PP2A 
to IP3R-PKB/Akt-protein complexes at the MAMs, where PP2A then dephosphorylates active Akt. 
BRCA1 binds to the C-terminal tail of IP3R (a.a. 2589-2749), thereby potentiating IP3R-mediated Ca
2+ 
signaling. 
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Highlights 
 Altered intracellular Ca2+ signaling is a hallmark of cancer cells. 
 Several oncogenes and tumor suppressors act at the endoplasmic reticulum, the main 
intracellular Ca2+ store. 
 These proteins execute part of their functions through the modulation of intracellular Ca2+ 
homeostasis and dynamics. 
 Dysregulation of oncogenes and tumor suppressors favors oncogenic Ca2+ signaling, 
supporting cell survival and tolerance to cell death. 
